Menu

Top Stories

Alpha-1 Hero Walk raises funds and awareness for Alpha-1

Alpha-1 Hero Walk raises funds and awareness for Alpha-1
Thursday, May 23, 2019
The 9th Annual Alpha-1 Hero Walk took place on May 4th, in Richmond, VA, where 75 attendees walked to raise awareness and funds for Alpha-1 Antitrypsin Deficiency (Alpha-1) research and related programs, exceeding $11,000. Pamela VanScoy, Walk Chair and Support Group Leader, was interviewed on Richmond's Morning News with John Reid, on WRVA Richmond - 1140 AM / 96.1 FM. Thank you, Pam,...
Divider

FDA warns of imposters sending consumers fake warning letters

Thursday, July 19, 2018
The U.S. Food and Drug Administration (FDA) is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or over the phone. Based on the agency’s experience with criminals...
Divider

Inhaled alpha-1 antitrypsin: Kamada receives positive advice on new Phase 3 study design

Tuesday, July 17, 2018
Kamada Ltd., a plasma-derived protein therapeutics company, announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), related to the development...
Divider

FDA announces recall of several medicines containing valsartan

Monday, July 16, 2018
The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This...
Divider

New working group for patient advocacy is created

Monday, July 16, 2018
The Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced newly selected representatives for the Patient Engagement Collaborative (PEC), a joint endeavor originally disclosed in December 2017 to...
Divider

Jonathan Maidment’s journey continues to develop

Tuesday, July 10, 2018
Jonathan Maidment, the 23-year old Alpha who undertook the challenge of doing a hike-thru of the entire 2,600-mile Pacific Coast Trail (PCT), from Southern California to the border between Washington state and Canada, interrupted his journey for...
Divider

CRISPR gene editing may correct Alpha-1 but perhaps it is too soon

Friday, July 6, 2018
Groundbreaking research shows that CRISPR-Cas9 genome editing technology can correct the gene mutation responsible for Alpha-1 Antitrypsin Deficiency (Alpha-1), by successfully making a targeted gene correction in the livers of affected mice that...
Divider

Tips for enjoying fireworks while living with Alpha-1 lung disease

Tuesday, July 3, 2018
Holidays are happy occasions, filled with celebrations with family and friends. The 4th of July usually includes barbecues, pool parties or beach trips. But if you or a loved one has Alpha-1, holidays can be daunting. The change of routine, the...
Divider

The 27th National Education Conference opens with a panel on the latest Alpha-1 findings

Friday, June 29, 2018
The 27th Annual Alpha-1 National Education Conference, organized by the Alpha-1 Foundation in San Francisco, California, will open this Friday, June 29th with a panel discussion about the latest therapies and tools in Alpha-1. The session will be...
Divider

The 27th Annual National Education Conference will be streaming online

Thursday, June 28, 2018
The 27th Annual Alpha-1 National Education Conference is the largest annual gathering of Alphas, their families, leading healthcare professionals and industry in the world. It is a three-day event with educational programs given by national...
Divider

Margaret Anderson will deliver keynote speech at the Alpha-1 Annual National Education Conference in San Francisco

Monday, June 25, 2018
Margaret Anderson, managing director of Deloitte Consulting LLP, will be the keynote speaker at the Alpha-1 Foundation’s 27th Annual National Education Conference on Saturday, June 29th at the Hyatt Regency San Francisco Airport in San...
Divider

Partnership aims at improving donor lung transplant

Wednesday, June 20, 2018
Paragonix Technologies, Inc. entered into a partnership with the Lung Transplant Foundation to support the company’s further development and subsequent commercialization of Paragonix SherpaLung™, a donor lung transport device for...
Divider

Arrowhead completes enrollment in Phase 1 study for treatment of Alpha-1 liver disease

Tuesday, June 19, 2018
Arrowhead Pharmaceuticals, Inc. announced that it has completed enrollment of a Phase 1 clinical trial of ARO-AAT, their second generation subcutaneously administered RNA interference (RNAi) therapeutic that is being developed as a treatment for...
Divider
First234567891011Last

Article Search

Enter keywords in text box and click Search button for results.

Archive